Lundbeck reports positive Phase IV results for Vyepti in migraine patients

The 24-week open-label trial evaluated 164 adults who had experienced inadequate responses to prior preventive treatments. Participants began with a 100 mg dose of eptinezumab, escalating to 300 mg at week 12. By the end of the study, the primary endpoint—measured by the Patient Global Impression of Change scale—showed that a clear majority of those remaining in the trial felt 'much' or 'very much' improved.

Tarek Samad, Lundbeck’s head of research and development, noted that the findings address a critical gap in migraine care for patients who continue to suffer despite existing preventive regimens. Beyond global improvement scores, researchers assessed reductions in monthly migraine and headache days alongside changes in acute medication use. The drug was generally well tolerated, with no new safety signals identified among the study population. Detailed results are expected to be presented at future scientific congresses.